BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

Home Media News & Media Explore the latest news from BioNTech, including press releases, media updates, and further press material for download. Oncology 09.14.2026 BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients Latest News 416 Results Press releaseOncology 10.22.2026 BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer Press releaseCorporate news 10.21.2026 BioNTech and Australia’s State of Victoria Celebrate Milestone in Strategic Partnership to Strengthen mRNA Ecosystem Press releaseFinancial news 10.20.2026 BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026 Press releaseOncology 10.19.2026 BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 Press releaseOncology 10.13.2026 BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer Press releaseOncology 09.14.2026 BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients OncologyStatement 08.28.2026 BioNTech Provides Update on Phase 2 Clinical Trial of Autogene Cevumeran in Resected Colorectal Cancer Press releaseCorporate news 08.27.2026 Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine Statement 08.27.2026 Update on Divestment of JPT Peptide Technologies GmbH as Part of BioNTech’s Planned Manufacturing Footprint Consolidation Press releaseOncology 08.20.2026 BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 Annual report 2025 In 2025, BioNTech has gained momentum in executing its strategy and shaping the future of medicine. Building on the foundation laid in recent years, we have accelerated our evolution with the aim of becoming a multi-product company. Access our 2025 annual report for insights into achievements, pipeline updates and a summary of our financial results. For healthcare professionals Our innovative research and development programs are focused on delivering transformative treatments for patients with cancer. We are committed to working with healthcare professionals to improve patient outcomes. For investors We are dedicated to driving shareholder value through strategic investments in innovative oncology therapies. Our leadership is committed to transparency and delivering long-term growth. Stay up to date You want to receive the latest information about our company by e-mail? Sign up to our mailing list.